Checkpoint Therapeutics Inc expected to post a loss of 15  cents a share - Earnings Preview

Checkpoint Therapeutics

04/03/2022 11:27

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 7 (estimated). 
    * The New York City-based  company is expected to report  a
159.3% increase in revenue to $70 thousand from $27 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of 15 cents per share. For the same quarter
last year, the company reported a loss of 17 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $20​, about 91.6% above​ its last closing
price of $1.68. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.13       -0.14      -0.14     Met     -2.9
 Jun. 30 2021  -0.10       -0.10      -0.12     Missed  -15.4
 Mar. 31 2021  -0.11       -0.10      -0.09     Beat    14.3​
 Dec. 31 2020  -0.08       -0.08      -0.17     Missed  -112.5
 ​​Sep.        -0.08       -0.08      -0.09     Missed  -12.5
 30 2020                                                
 Jun. 30 2020  -0.09       -0.09      -0.09     Met     0​
 Mar. 31 2020  -0.13       -0.13      -0.06     Beat    52.6
 Dec. 31 2019  -0.17       -0.17      -0.22     Missed  -32
 This summary was machine generated March 4 at 11:27 GMT.  All
figures in US dollars  unless otherwise stated